文献速递骨质疏松与代谢性骨病创伤骨科

在骨折联络服务就诊的近期骨折患者中启动抗骨质疏松药物治疗决策辅助工具的开发与可用性研究

Development and usability of a decision aid to initiate anti-osteoporosis medication treatment in patients visiting the fracture liaison service with a recent fracture.
PubMed 文献 · Osteoporos Int · 2023-09-21

本研究依据国际患者决策辅助标准(IPDAS)开发了一款决策辅助工具(DA),用于支持近期骨折且合并骨质疏松或存在椎体骨折的患者决定是否启动抗骨质疏松药物治疗(AOM)。α测试中15例患者认为该DA充分呈现了患者偏好与需求,并提出若干改进建议且被采纳;参与α测试者推荐在门诊就诊时使用该DA。专业人员与骨质疏松患者均支持该DA及其可用性,作者认为该DA可帮助患者与医疗保健提供者(HCPs)进行共享决策,并已启动一项实验性研究评估该DA的(成本)效果。

要点

  • 该决策辅助工具依据国际患者决策辅助标准(IPDAS)开发,内容涵盖骨折与骨质疏松信息、后续骨折的一般危险因素、生活方式的作用、用与不用AOM治疗的个体化后续骨折风险考量,以及以选项网格呈现的AOM选项及其特征。
  • α测试纳入15例患者,结果显示患者偏好与需求得到充分呈现,若干改进建议(如增加更具体信息、简化术语、改进图标使用)已被采纳。
  • 参与α测试者推荐在门诊就诊时使用该决策辅助工具;作者认为该工具可帮助患者与医疗保健提供者进行共享决策。

核心结论

  • 专业人员与骨质疏松患者均支持所提出的决策辅助工具及其可用性。
  • 该决策辅助工具可帮助患者与医疗保健提供者进行共享决策。
  • 已启动一项实验性研究以评估该决策辅助工具的(成本)效果。

研究设计与样本

  • 本研究依据国际患者决策辅助标准(IPDAS)开发决策辅助工具(DA),采用包括范围界定、设计、原型开发和α测试的系统化流程。
  • 开发以先前为女性骨质疏松患者开发的DA为基础,并结合文献检索、荷兰骨质疏松管理指南以及骨折或骨质疏松患者的意见。
  • α测试纳入15例患者对更新后的DA进行评价。

主要发现

  • 该DA促进患者就是否启动AOM治疗做出决策,并提供骨折与骨质疏松、增加后续骨折可能性的通用危险因素、生活方式的作用、用与不用AOM治疗时后续骨折的个体化风险考量,以及以选项网格呈现的AOM选项及其特征等信息。
  • α测试中15例患者显示患者偏好与需求得到充分呈现,若干改进建议(如增加更具体信息、简化术语、改进图标使用)已被采纳。
  • 参与α测试者推荐在门诊就诊时使用该DA。

临床怎么用

  • 参与α测试者推荐在门诊就诊时使用该决策辅助工具。
  • 作者认为该决策辅助工具可帮助患者与医疗保健提供者进行共享决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study describes the development of a decision aid (DA), aimed at supporting patients in their decision whether to start anti-osteoporosis medication. People with recent fractures or osteoporosis and health professionals were supportive of the DA initiative. An experimental study been started to assess (cost-)effectiveness of the DA. PURPOSE: At fracture liaison services (FLS), patients with a recent fracture ánd osteoporosis or a prevalent vertebral fracture are advised to start anti-osteoporosis medication (AOM). This study describes the development of a decision aid (DA) to support patients and healthcare providers (HCPs) in their decision about whether to start AOM. METHODS: The DA was developed according to International Patient Decision Aid Standards (IPDAS). A systematic procedure was chosen including scope, design, prototype development, and alpha testing. A previously developed DA for women with osteoporosis was used as a basis. Furthermore, input from literature searches, the Dutch guideline on management of osteoporosis, and from people with a fracture or osteoporosis was used. The updated DA was evaluated during alpha testing. RESULTS: The DA facilitates the decision of patients whether to initiate AOM treatment and provides information on fractures and osteoporosis, general risk factors that increase the likelihood of a subsequent fracture, the role of lifestyle, personalized risk considerations of a subsequent fracture with and without AOM treatment, and AOM options and their characteristics in an option grid. Alpha testing with 15 patients revealed that patient preferences and needs were adequately presented, and several suggestions for improvement (e.g. adding more specific information, simplifying terminology, improving icon use) were accounted for. Participants from the alpha testing recommended use of the DA during outpatient visits. CONCLUSION: Professionals and persons with osteoporosis were supportive of the proposed DA and its usability. The DA could help in a shared decision-making process between patients and HCPs.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Maas L, Raskin N, van Onna M, et al. Development and usability of a decision aid to initiate anti-osteoporosis medication treatment in patients visiting the fracture liaison service with a recent fracture. Osteoporos Int. 2023. PMID: 37733067. doi:10.1007/s00198-023-06906-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。